Breaking News Instant updates and real-time market news.

ALDX

Aldeyra

$7.14

-0.31 (-4.16%)

07:02
03/26/19
03/26
07:02
03/26/19
07:02

Aldeyra announces results from Phase 3 Alleviate Trial

Aldeyra Therapeutic announced positive results from the Phase 3 ALLEVIATE Trial of 0.25% and 0.5% reproxalap topical ophthalmic solution in patients with allergic conjunctivitis. The clinical trial met the primary endpoint and the key secondary endpoint for both concentrations of reproxalap. The company commented, "Consistent with positive results from five prior Phase 2 clinical trials in ocular inflammation, today's announcement confirms the potential of reproxalap as a novel and clinically meaningful approach for the treatment of allergic conjunctivitis. Given that approximately half of allergic conjunctivitis patients also suffer from ocular dryness, we believe the ALLEVIATE results highlight the relevance of reproxalap to our current Phase 3 program in dry eye disease." The double-masked, randomized, vehicle-controlled, multi-center, parallel-group conjunctival allergen challenge Phase 3 ALLEVIATE trial assessed the efficacy and safety of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solutions compared to vehicle in 318 patients with seasonal allergic conjunctivitis.

  • 26

    Mar

ALDX Aldeyra
$7.14

-0.31 (-4.16%)

09/26/18
ADAM
09/26/18
NO CHANGE
Target $35
ADAM
Buy
Aldeyra price target raised to $35 from $27 at Canaccord
Canaccord analyst John Newman raised his price target on Aldeyra shares to $35 from $27 after the company's Phase 2b trial of topical ocular reproxalap in patients with dry eye disease achieved statistically significant improvement against vehicle for all imputation techniques, which he called a "major positive." The very rapid onset of action is differentiating, said the analyst, who expects positive Phase 3 dry eye data given the Phase 2b results. He maintains a Buy rating on Aldeyra shares.
09/26/18
STFL
09/26/18
NO CHANGE
Target $36
STFL
Buy
Aldeyra price target raised to $36 from $16 at Stifel
Stifel analyst Adam Walsh believe Aldeyra's "strong" reproxalap trial results in dry eye disease position the company as "a legitimate player in this blockbuster market." Safety was clean, tolerability was in-line with approved treatments and the early onset of action makes reproxalap look highly differentiated, Walsh added. While Aldeyra likely needs to raise capital to run its two planned dry eye disease Phase 3 trials, Walsh believes the current valuation appears attractive, he tells investors. The analyst raised his price target on Aldeyra shares to $36 from $16 and keeps a Buy rating on the stock.
12/04/18
SBSH
12/04/18
INITIATION
Target $23
SBSH
Buy
Aldeyra initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Aldeyra Therapeutics with a Buy rating and $23 price target. The analyst points out the company's late-stage clinical asset reproxalap is being developed in three eye indications. He models worldwide risk-adjusted revenues of $400M.
02/15/19
SBSH
02/15/19
NO CHANGE
SBSH
Buy
Citi opens 90-day 'positive catalyst watch' on Aldeyra
Citi analyst Yigal Nochomovitz opened a 90-day catalyst watch on Aldeyra in anticipation of the Phase 3 Alleviate data in Q1 for reproxalap in allergic conjunctivitis. On positive data, the analyst expects the stock to be up 75% to 125%. He keeps a Buy rating on Aldeyra.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.